MedTrace Logo

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)

NCT03851939 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2019-02-22

No results posted yet for this study

Summary

To evaluate the efficacy of TAI combine toripalimab in advanced HCC.

Conditions

Interventions

COMBINATION_PRODUCT

Transarterial Chemoinfusion (TAI) Combine Toripalimab

Transarterial Chemoinfusion (TAI) Combine Toripalimab

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-26
Primary Completion
2020-03-01
Completion
2021-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03851939 on ClinicalTrials.gov